HONG KONG, July 28, 2023 /PRNewswire/ In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical.
The U.S. company Arthrosi Therapeutics has bagged $75 million in a Series D round to fund the clinical development of a small molecule drug for chronic gout.
ARTHROSI SECURES $75M IN SERIES D FINANCING streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Arthrosi Therapeutics, a clinical-stage biotechnology company, today announced the successful securing of $75 million in Series D financing..